DNA — Ginkgo Bioworks Holdings, Inc.

—
NYSE · Health Care · Biotechnology · CIK 1830214 ·
Last close
$10.66
Market Cap
$590.39M
52W High
$17.58
52W Low
$5.37
ADV30
1,455,980
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 20,156,000 18,437,000 -58,548,000 -46,710,000 990,046,000 84,535,000 569,762,000
Mar 2026 19,474,000 16,376,000 -71,374,000 -82,587,000 1,033,075,000 143,864,000 589,922,000
Dec 2025 33,396,000 26,095,000 -70,046,000 -80,751,000 1,119,696,000 167,202,000 611,106,000
Sep 2025 38,837,000 26,035,000 -88,272,000 -80,755,000 1,189,165,000 111,065,000 629,382,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-178,360,000
Investing CF
$56,502,000
Financing CF
$34,550,000
CapEx
$-4,595,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.69
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-6,279,617,000
Inventory
—
Receivables
$13,013,000
ST Investments
$217,628,000
EBIT TTM
$-297,960,000
Pretax Income TTM
$-295,480,000
Interest Exp TTM
—
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$132,421,000
EBITDA
$-261,624,992
Free Cash Flow
$-72,398,248
Enterprise Value
$556,496,896
Total Cash
$302,163,008
Total Debt
$404,112,992
Shares Out
55,383,808
Trailing EPS
$-5.33
Book Value
$6.60
ROE
-59.9%
ROA
-16.7%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 170,155,000 -303,880,000 -312,763,000 1,119,696,000 611,106,000 508,590,000 -171,059,000
Dec 2024 227,043,000 -487,727,000 -547,029,000 1,377,449,000 661,391,000 716,058,000 -319,585,000
Dec 2023 251,455,000 -768,196,000 -892,869,000 1,665,342,000 568,190,000 1,097,152,000 -295,500,000
Dec 2022 477,706,000 -2,208,952,000 -2,104,929,000 2,539,321,000 803,044,000 1,736,277,000 -252,198,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.90

Max Pain — expiry 2026-12-18

max pain strike: $8.00 · spot: $10.41 · call oi: 8,132 · put oi: 895
Expected Move to 2026-12-18: ±$4.20 (40.35%) — implied range $6.21 – $14.61 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VALN Valneva SE $582.22M $6.14 —
ALLO Allogene Therapeutics, Inc. $570.06M $1.65 —
AURA Aura Biosciences, Inc. $622.23M $6.00 —
PRME Prime Medicine, Inc. $525.99M $2.90 —
AGMB AgomAb Therapeutics NV $517.60M $10.51 —

News headlines (Yahoo Finance, 1h cache)

Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
2026-09-23 22:15 · Yahoo
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts
2026-09-16 22:15 · Yahoo
Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
2026-09-16 13:52 · Yahoo
Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
2026-09-10 12:00 · Yahoo
The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts
2026-05-13 11:41 · Yahoo
Ginkgo Bioworks Q2 Earnings Call Highlights
2026-08-08 04:03 · Yahoo
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
2026-05-26 16:33 · Yahoo
Ginkgo Bioworks Q1 Earnings Call Highlights
2026-05-10 03:05 · Yahoo
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
2026-05-07 20:05 · Yahoo
Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
2026-04-30 12:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.